Lipoprotein
No dementia, cognitive risk with PCSK9 inhibition; statin findings mixed
Data from a genetics-based study show PCSK9 inhibition does not affect cognition function or dementia risk; however, statin use may be associated with some impaired cognitive performance that is outweighed by any CV benefits.
Short interfering RNA therapy dramatically lowers Lp(a) in phase 1 trial
WASHINGTON — In the phase 1 APOLLO study, a short interfering RNA therapy lowered lipoprotein(a) by a maximum of more than 90% in certain doses, researchers reported at the American College of Cardiology Scientific Session.
Top in cardiology: Benefits of chewing gum after surgery, updates in lipid research
Recent data presented at the virtual Society of Thoracic Surgeons Perioperative and Critical Conference suggested that chewing gum may accelerate gut function among cardiac surgery patients. It was the top story in cardiology last week.
Certain lipoprotein particles may increase risk for MI, PAD in women
Triglyceride-rich lipoprotein cholesterol was strongly linked to future peripheral artery disease and MI events in women, according to a study published in the Journal of the American College of Cardiology.
Top stories from CMHC: Statin intolerance, Lp(a) impact on CV risk and more
Healio and Cardiology Today present meeting highlights from the Cardiometabolic Health Congress. From the meeting, Healio readers were interested in statin intolerance, wearable devices, metabolic syndrome, health technology and more.
Lipid levels decreased since publication of 2013 cholesterol guidelines
Lipid and lipoprotein levels have declined since the 2013 American College of Cardiology/American Heart Association cholesterol guidelines were published, according to a study published in the Journal of the American College of Cardiology.
Intervention improves adherence to Mediterranean diet, intermittent statin dosing shows promise — top stories in cardiology
Despite new guidelines, CVD prevention barriers remain for some patients
CHICAGO — Updated guidelines provide clear CVD prevention strategies for most patients, but barriers to optimal treatment in some patients remain, including issues related to sex, age, inflammation and adequate testing, according to a speaker.
Lp(a) has strong effect on CVD risk
CHICAGO — Lipoprotein(a) has been shown to be an independent, causal and genetic risk factor for CVD, with higher prevalence in patients of African, South Asian, Asian and Oceanic ancestry, according to a presentation at the Cardiometabolic Health Congress.
Volanesorsen decreases triglycerides in familial chylomicronemia syndrome
Volanesorsen reduced triglycerides in 77% of patients with familial chylomicronemia syndrome to less than 750 mg/dL, according to a study published in The New England Journal of Medicine.